Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
36 hedge funds and large institutions have $3.4M invested in Navidea Biopharmaceuticals Inc. in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 3 closing their positions.
7% less call options, than puts
Call options by funds: $351K | Put options by funds: $377K
5% less funds holding
Funds holding: 38 → 36 (-2)
22% less capital invested
Capital invested by funds: $4.34M → $3.4M (-$939K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$86.9K |
| 2 |
Two Sigma Advisers
New York
|
+$86K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$36.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.6K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$95.4K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$53.3K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$44.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31.3K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$29.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JCM
26
Jacobi Capital Management
Pittston,
Pennsylvania
| $2K | – | – | – |
|
|
ASN
27
Advisory Services Network
Atlanta,
Georgia
| $1K | – | – | – |
|
|
PA
28
Parallel Advisors
San Francisco,
California
| $1K | – | – | – |
|
|
SIS
29
Sound Income Strategies
Ft Lauderdale,
Florida
| $1K | – | – | – |
|
|
KFS
30
Kelly Financial Services
Braintree,
Massachusetts
| $108 | – | – | – |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -2,000 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$4K | -1,317 | Closed |
|
|
HPC
33
HM Payson & Co
Portland,
Maine
| – | -$1K | -300 | Closed |
|
34
Osaic Holdings
Scottsdale,
Arizona
| – | -$707 | -300 | -98% |
|
|
OSAM
35
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | +$212 | +90 | +176% |
|
NAVB Hedge Fund Activity: Q4 2020 in Review
36 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2020, worth a combined $3.4M — down 22% from $4.34M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NAVB and 2 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 7 added.
The largest buyer was Two Sigma Investments, adding an estimated $86.9K. The largest seller was Renaissance Technologies, cutting an estimated $95.4K.
- 36 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2020, down from 38 in Q3 2020.
- Funds reported $3.4M of Navidea Biopharmaceuticals Inc. stock for Q4 2020, down 22% quarter-over-quarter.
- 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2020 and 3 closed out, a net change of -1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2020 was Two Sigma Investments, an estimated $86.9K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2020 was Renaissance Technologies, an estimated $95.4K sold.
Based on aggregated 13F filings for Q4 2020.